Biontech is making further progress in developing a corona vaccine. An initial study indicates the potential of the vaccine BNT162b2. The next phase with up to 30,000 test persons is already underway. If everything goes well, large-scale production could start soon.
The Mainz biotech company Biontech is planning to apply for approval for its corona vaccine as early as October if the study results are positive. If approved, Biontech and its partner Pfizer could provide up to 100 million vaccine doses worldwide by the end of 2020 and potentially around 1.3 billion vaccine doses by the end of 2021, the company affirmed.
The most recent data from the phase 1 study with the vaccine BNT162b2 support its selection for the pivotal study that started in July with up to 30,000 participants. "In particular, the advantageous safety profile of BNT162b2 and the previously announced broad T-cell immune response supported our decision to select this candidate for the pivotal phase 2/3 study," said Biontech boss Ugur Sahin.
So far, more than 11,000 subjects have been vaccinated and would soon receive the second vaccination, including in regions with a "significant" risk of transmission of the coronavirus. According to the World Health Organization [WHO], there are currently 169 corona vaccine projects worldwide, 30 of which are in clinical trials on humans, eight of them in the crucial final phase 3 study, which is decisive for approval.
.